alexa Posaconazole: a broad-spectrum triazole antifungal.


Advancements in Genetic Engineering

Author(s): Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II

Abstract Share this page

Abstract Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi. Posaconazole is given orally two to four times daily. This triazole is widely distributed in the body, metabolised mainly by the liver, and is well tolerated, even in long-term courses. Adverse events are generally mild and include headache and gastrointestinal complaints. Posaconazole has shown promising clinical efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies-eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis. This article was published in Lancet Infect Dis and referenced in Advancements in Genetic Engineering

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • International Conference on Epigenetics 2017
    November 13-15, 2017 Frankfurt, Germany
  • International Conference on Genetic Counseling and Genomic Medicine
    February 12-13, 2018 Madrid, Spain

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version